CN1254260C - 含淫羊藿提取物的药物组合物 - Google Patents
含淫羊藿提取物的药物组合物 Download PDFInfo
- Publication number
- CN1254260C CN1254260C CN 200410034456 CN200410034456A CN1254260C CN 1254260 C CN1254260 C CN 1254260C CN 200410034456 CN200410034456 CN 200410034456 CN 200410034456 A CN200410034456 A CN 200410034456A CN 1254260 C CN1254260 C CN 1254260C
- Authority
- CN
- China
- Prior art keywords
- extract
- epimedium
- ethanol
- parts
- pollen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000020696 epimedium extract Nutrition 0.000 title claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 18
- 150000004676 glycans Chemical class 0.000 claims abstract description 61
- 241000893536 Epimedium Species 0.000 claims abstract description 57
- 235000018905 epimedium Nutrition 0.000 claims abstract description 56
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 55
- 239000005017 polysaccharide Substances 0.000 claims abstract description 55
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 52
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 52
- 239000000284 extract Substances 0.000 claims abstract description 46
- 201000007094 prostatitis Diseases 0.000 claims abstract description 19
- 241000972672 Phellodendron Species 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 241000208340 Araliaceae Species 0.000 claims abstract description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 112
- 229930003935 flavonoid Natural products 0.000 claims description 52
- 150000002215 flavonoids Chemical class 0.000 claims description 52
- 235000017173 flavonoids Nutrition 0.000 claims description 52
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 14
- 235000006533 astragalus Nutrition 0.000 claims description 13
- 235000019206 astragalus extract Nutrition 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 235000020710 ginseng extract Nutrition 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 150000004804 polysaccharides Polymers 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 150000007949 saponins Chemical group 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 2
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 2
- 241000045403 Astragalus propinquus Species 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 2
- 229930003944 flavone Natural products 0.000 abstract description 2
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 2
- 235000011949 flavones Nutrition 0.000 abstract description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 2
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 208000013507 chronic prostatitis Diseases 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 14
- 241001061264 Astragalus Species 0.000 description 12
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 210000004233 talus Anatomy 0.000 description 12
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 10
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 206010046555 Urinary retention Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 208000032023 Signs and Symptoms Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- IYCPMVXIUPYNHI-WPKKLUCLSA-N 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-WPKKLUCLSA-N 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 206010029446 nocturia Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001362421 Epimedium brevicornu Species 0.000 description 3
- 241000893531 Epimedium koreanum Species 0.000 description 3
- 241001362411 Epimedium sagittatum Species 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- 229940093265 berberine Drugs 0.000 description 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 206010036596 premature ejaculation Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 241000133570 Berberidaceae Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 241001660849 Epimedium pubescens Species 0.000 description 2
- 241001362415 Epimedium wushanense Species 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700608 Sagitta Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001016310 Epimedium grandiflorum Species 0.000 description 1
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010060926 abdominal symptom Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
| 种名 | 产地 | 含量(%) | |||
| 淫羊藿甙 | 淫羊藿甙I | 总黄酮 | 总多糖 | ||
| 淫羊藿 | 陕西 | 1.193 | 0.445 | 12.3 | 20.7 |
| 四川 | 1.088 | 0.794 | 11.6 | 19.0 | |
| 箭叶淫羊藿 | 湖南 | 0.961 | 0.190 | 7.2 | 15.9 |
| 湖北 | 0.735 | 0.110 | 6.4 | 13.4 | |
| 贵州 | 3.098 | 0.084 | 18.3 | 26.1 | |
| 巫山淫羊藿 | 四川 | 3.343 | 0.094 | 20.1 | 25.6 |
| 贵州 | 2.882 | 0.030 | 8.9 | 20.1 | |
| 柔毛淫羊藿 | 四川 | 1.140 | 0.067 | 10.2 | 18.6 |
| 朝鲜淫羊藿 | 辽宁 | 0.890 | 0.104 | 16.9 | 22.5 |
| 种名 | 产地 | A部分得率 | B部分得率 |
| 淫羊藿 | 陕西 | 20g,4% | 37g,7.4% |
| 四川 | 10g,3% | 29g,5.8% |
| 箭叶淫羊藿 | 湖南 | 12g,2.4% | 20g,4.0% |
| 湖北 | 8g,1.6% | 30g,6.0% | |
| 贵州 | 27g,5.8% | 39g,7.8% | |
| 巫山淫羊藿 | 四川 | 23g,4.6% | 42g,8.4% |
| 贵州 | 16g,3.2% | 32g,6.4% | |
| 柔毛淫羊藿 | 四川 | 9g,1.8% | 25g,5.0% |
| 朝鲜淫羊藿 | 辽宁 | 18g,3.6% | 28g,5.6% |
| 组别 | 例数 | 年龄(岁) | 病程(年) | 合并性功能障碍例数 |
| 良性前列腺肥大* | 32 | 64.90±7.8 | 11.5±8.7 | |
| 前列腺肥大伴慢性前列腺炎** | 24 | 42.42±12.1 | 3.5±3.3 | 24 |
| 症状体征 | 0分 | 1分 | 2分 | 3分 |
| 排尿状况小腹症状排尿时间尿流率残留尿量前列腺肥大 | 正常无<40秒>15ml/秒10ml正常 | 尿细或线状满闷感40-50秒11-15ml/秒10-50mlI度增生 | 尿流断续成线状胀满感51-60秒6-10ml/秒50-100mlII度增生 | 尿点滴而下,不成线胀满痛>60秒<6ml/秒>100mlIII度增生 |
| 分组 | 治前积分 | 治后积分 | P值 |
| 良性前列腺肥大 | 12.16±2.42 | 6.26±1.98 | P<0.01 |
| 良性前列腺肥大伴炎症 | 10.42±2.54 | 4.88±2.82 | P<0.01 |
| 分组 | 治前 | 治后积分 | P值 |
| 良性前列腺肥大 | 65.93±60.19 | 37.19±43.05 | P<0.05 |
| 良性前列腺肥大伴炎症 | 45.83±53.48 | 25.41±34.38 | P<0.05 |
| 分组 | 治前 | 治后积分 | P值 |
| 良性前列腺肥大 | 4.41±1.44 | 7.74±3.33 | P<0.01 |
| 良性前列腺肥大伴炎症 | 7.02±3.29 | 10.91±5.46 | P<0.01 |
| 分组 | 治前 | 治后积分 | P值 |
| 良性前列腺肥大 | 3.31±3.68 | 3.03±3.84 | P>0.05 |
| 良性前列腺肥大伴炎症 | 4.41±5.28 | 1.84±1.07 | P<0.01 |
| 分组 | 例数 | 控制 | 显效 | 有效 | 无效 | 总有效 | 总有效率 |
| 肥大组 | 32 | 2 | 12 | 16 | 2 | 30 | 93.8% |
| 肥大兼炎症组 | 24 | 1 | 6 | 11 | 6 | 18 | 75.0% |
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410034456 CN1254260C (zh) | 2002-12-18 | 2002-12-18 | 含淫羊藿提取物的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410034456 CN1254260C (zh) | 2002-12-18 | 2002-12-18 | 含淫羊藿提取物的药物组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021485712A Division CN1194702C (zh) | 2002-12-18 | 2002-12-18 | 治疗前列腺肥大的淫羊藿提取物及其在制备药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1548145A CN1548145A (zh) | 2004-11-24 |
| CN1254260C true CN1254260C (zh) | 2006-05-03 |
Family
ID=34352241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410034456 Expired - Lifetime CN1254260C (zh) | 2002-12-18 | 2002-12-18 | 含淫羊藿提取物的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1254260C (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100500160C (zh) * | 2007-05-11 | 2009-06-17 | 澳美制药厂有限公司 | 含淫羊藿有效成分的药物组合物及其用途 |
| JP6034293B2 (ja) * | 2010-11-05 | 2016-11-30 | ベイジン チョンアン アジュバント バイオテクノロジー カンパニー,リミティド | イカリソウの多糖、その画分、及びワクチンアジュバントとしてのその使用 |
| CN103613675B (zh) * | 2010-11-05 | 2016-08-17 | 北京中安佐际生物科技有限公司 | 淫羊藿多糖及其组分和它们用于疫苗佐剂的用途 |
-
2002
- 2002-12-18 CN CN 200410034456 patent/CN1254260C/zh not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1548145A (zh) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101062165A (zh) | 枳实总黄酮提取物及其制备方法 | |
| CN101073599A (zh) | 丹参中总丹参酮及总酚酸提取物及其制备方法 | |
| CN104013668B (zh) | 甘草黄酮类提取物用于制备治疗溃疡性结肠炎药物中应用 | |
| CN100560083C (zh) | 一种从中药三七中提取纯化总皂苷的制备方法 | |
| CN1194702C (zh) | 治疗前列腺肥大的淫羊藿提取物及其在制备药物中的应用 | |
| CN101062074A (zh) | 冬虫夏草菌和三七提取物的组合物及其在防治肺纤维化上的应用 | |
| CN100534508C (zh) | 一种制备菝葜有效部位群的方法 | |
| CN1254260C (zh) | 含淫羊藿提取物的药物组合物 | |
| CN1899491A (zh) | 一种重楼总皂苷的制备方法及其用途 | |
| CN102362971A (zh) | 一种治疗冠心病中药及其有效化学组分的制备方法和制剂 | |
| CN1814149A (zh) | 一种治疗糖尿病或糖尿病肾病的药物组合物及其制备方法 | |
| CN108904521B (zh) | 一种含百尾参多糖的抗肿瘤药物及其使用方法 | |
| CN101721450B (zh) | 一种用于治疗腹膜炎的苍耳根氯仿提取物的应用 | |
| HK1056508B (zh) | 治療前列腺肥大的淫羊藿提取物及其在製備藥物中的應用 | |
| HK1056508A1 (zh) | 治療前列腺肥大的淫羊藿提取物及其在製備藥物中的應用 | |
| CN101229204A (zh) | 一种柴胡总皂苷的制备方法 | |
| HK1071073B (zh) | 含淫羊藿提取物的药物组合物 | |
| CN100343266C (zh) | 一种胡黄连总苷提取物及其在制备肝病药物中的应用和制备方法 | |
| CN101461842B (zh) | 夏枯草抗肿瘤有效部位的提取方法及其提取物在制备抗肿瘤药物方面的应用 | |
| CN105012484A (zh) | 一种治疗化脓性鼻窦炎的药物制剂及其制备方法 | |
| CN1237984C (zh) | 一种抗癌中药冻干粉针剂及其制备方法 | |
| CN101181336A (zh) | 一种苦瓜降血糖有效部位的精制方法 | |
| CN100400048C (zh) | 锦灯笼多糖在制备治疗糖尿病药物和保健品中的应用 | |
| CN1973853A (zh) | 一种止血镇痛的药物组合物及其制备方法 | |
| CN101411778A (zh) | 一种中药有效部位组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1071073 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20041124 Assignee: SHENZHEN BRIGHT FUTURE TECHNOLOGY DEVELOPMENT CO.,LTD. Assignor: BRIGHT FUTURE PHARMACEUTICAL LABORATORIES LTD. Contract record no.: 2015990000378 Denomination of invention: Medicine composition containing epimedium extract Granted publication date: 20060503 License type: Exclusive License Record date: 20150526 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060503 |